Literature DB >> 26770305

Autotaxin-LPA receptor axis in the pathogenesis of lung diseases.

Xiangpeng Chu1, Xiaojie Wei1, Shaolin Lu1, Peijian He2.   

Abstract

Lysophosphatidic acid (LPA) is a small lipid which mediates a variety of cellular functions via the activation of LPA receptors. LPA is generated from lysophosphatidylcholine by the extracellular enzyme, autotaxin (ATX). Elevated ATX expression, LPA production and their signaling pathways have been reported in multiple pathological conditions of lung tissue, including inflammation, fibrosis and cancer. Emerging evidence has highlighted the importance of ATX and LPA receptors in the pathogenesis of lung diseases. Here, we briefly review the current knowledge of different roles of the ATX-LPA receptor axis in lung diseases focusing on inflammation, fibrosis and cancer.

Entities:  

Keywords:  Lysophosphatidic acid receptor; autotaxin; lung diseases

Year:  2015        PMID： 26770305      PMCID： PMC4694205     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN： 1940-5901


  41 in total

1.  A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.

Authors:  J S Swaney; C Chapman; L D Correa; K J Stebbins; R A Bundey; P C Prodanovich; P Fagan; C S Baccei; A M Santini; J H Hutchinson; T J Seiders; T A Parr; P Prasit; J F Evans; D S Lorrain
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Autotaxin and LPA receptor signaling in cancer.

Authors:  Anna J S Houben; Wouter H Moolenaar
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model.

Authors:  Xiaoyu Xu; Glenn D Prestwich
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

Review 4.  Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling.

Authors:  Yutong Zhao; Viswanathan Natarajan
Journal:  Biochim Biophys Acta       Date:  2012-07-15

5.  Autotaxin expression in non-small-cell lung cancer.

Authors:  Y Yang; Lj Mou; N Liu; M S Tsao
Journal:  Am J Respir Cell Mol Biol       Date:  1999-08       Impact factor: 6.914

6.  The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.

Authors:  Ahmed Boucharaba; Claire-Marie Serre; Julien Guglielmi; Jean-Claude Bordet; Philippe Clézardin; Olivier Peyruchaud
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-12       Impact factor: 11.205

Review 7.  Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.

Authors:  Semjon Willier; Elke Butt; Thomas G P Grunewald
Journal:  Biol Cell       Date:  2013-06-03       Impact factor: 4.458

Review 8.  LPA and its analogs-attractive tools for elucidation of LPA biology and drug development.

Authors:  Kuniyuki Kano; Naoaki Arima; Mitsuru Ohgami; Junken Aoki
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak.

Authors:  Andrew M Tager; Peter LaCamera; Barry S Shea; Gabriele S Campanella; Moisés Selman; Zhenwen Zhao; Vasiliy Polosukhin; John Wain; Banu A Karimi-Shah; Nancy D Kim; William K Hart; Annie Pardo; Timothy S Blackwell; Yan Xu; Jerold Chun; Andrew D Luster
Journal:  Nat Med       Date:  2007-12-09       Impact factor: 53.440

10.  LPA induces IL-6 secretion from aortic smooth muscle cells via an LPA1-regulated, PKC-dependent, and p38alpha-mediated pathway.

Authors:  Feng Hao; Mingqi Tan; Daniel D Wu; Xuemin Xu; Mei-Zhen Cui
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-31       Impact factor: 4.733
View more
  9 in total

1.  Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice.

Authors:  Ya-Lan Dong; Xue-Yun Duan; Yu-Jin Liu; Heng Fan; Meng Xu; Qian-Yun Chen; Zhen Nan; Hui Wu; Shuang-Jiao Deng
Journal:  Inflammation       Date:  2019-10       Impact factor: 4.092

2.  Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.

Authors:  Manuel Baader; Tom Bretschneider; Andre Broermann; Joerg F Rippmann; Birgit Stierstorfer; Christian A Kuttruff; Michael Mark
Journal:  Br J Pharmacol       Date:  2018-01-17       Impact factor: 8.739

3.  Metabolomics analysis reveals that benzo[a]pyrene, a component of PM2.5, promotes pulmonary injury by modifying lipid metabolism in a phospholipase A2-dependent manner in vivo and in vitro.

Authors:  Song-Yang Zhang; Danqing Shao; Huiying Liu; Juan Feng; Baihuan Feng; Xiaoming Song; Qian Zhao; Ming Chu; Changtao Jiang; Wei Huang; Xian Wang
Journal:  Redox Biol       Date:  2017-07-04       Impact factor: 11.799

4.  Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD.

Authors:  Shama Naz; Johan Kolmert; Mingxing Yang; Stacey N Reinke; Muhammad Anas Kamleh; Stuart Snowden; Tina Heyder; Bettina Levänen; David J Erle; C Magnus Sköld; Åsa M Wheelock; Craig E Wheelock
Journal:  Eur Respir J       Date:  2017-06-22       Impact factor: 16.671

5.  Adult Lysophosphatidic Acid Receptor 1-Deficient Rats with Hyperoxia-Induced Neonatal Chronic Lung Disease Are Protected against Lipopolysaccharide-Induced Acute Lung Injury.

Authors:  Xueyu Chen; Frans J Walther; El H Laghmani; Annemarie M Hoogeboom; Anne C B Hogen-Esch; Ingrid van Ark; Gert Folkerts; Gerry T M Wagenaar
Journal:  Front Physiol       Date:  2017-03-22       Impact factor: 4.566

6.  Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.

Authors:  Ellen van der Aar; Julie Desrivot; Sonia Dupont; Bertrand Heckmann; Ann Fieuw; Simone Stutvoet; Liesbeth Fagard; Karen Van de Wal; Eric Helmer
Journal:  J Clin Pharmacol       Date:  2019-04-23       Impact factor: 3.126

7.  Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease.

Authors:  Qingling Li; Weng Wong; Andrew Birnberg; Arindam Chakrabarti; Xiaoying Yang; David F Choy; Julie Olsson; Erik Verschueren; Margaret Neighbors; Wendy Sandoval; Carrie M Rosenberger; Michele A Grimbaldeston; Gaik W Tew
Journal:  BMC Pulm Med       Date:  2021-09-23       Impact factor: 3.317

Review 8.  Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.

Authors:  Matthew G K Benesch; Iain T K MacIntyre; Todd P W McMullen; David N Brindley
Journal:  Cancers (Basel)       Date:  2018-03-15       Impact factor: 6.639

9.  A Novel Therapeutic Reagent, KA-1002 for Alleviating Lysophosphatidic Acid-Mediated Inflammation Related Gene Expression in Swine Macrophages.

Authors:  Hyeon-Jeong Hwang; Tamina Park; Miok Kim; Hee-Su Shin; Wooyeon Hwang; Yong Ki Min; Suk-Gil Song; Daeui Park; Chang Hoon Lee
Journal:  Animals (Basel)       Date:  2020-03-23       Impact factor: 2.752
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.